Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

References

• Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4:306–322. doi:10.1016/S2213-2600(15)00543-3
   PubMed Web of Science ®Google Scholar
• McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62:D51–9. doi:10.1016/j.jacc.2013.10.023
   PubMed Web of Science ®Google Scholar
• Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14:603–614. doi:10.1038/nrcardio.2017.84
   PubMed Web of Science ®Google Scholar
• Sofer A, Ryan MJ, Tedford RJ, Wirth JA, Fares WH. A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulm Circ. 2017;7:326–338. doi:10.1177/2045893217706357
   PubMed Web of Science ®Google Scholar
• Gu S, Hu H, Dong H. Systematic review of the economic burden of pulmonary arterial hypertension. PharmacoEconomics. 2016;34:533–550. doi:10.1007/s40273-015-0361-0
   PubMed Web of Science ®Google Scholar
• Zhai Z, Zhou X, Zhang S, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine. 2017;96:e6783. doi:10.1097/MD.0000000000006783
   PubMed Web of Science ®Google Scholar
• Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011;140:301–309. doi:10.1378/chest.10-2327
   PubMed Web of Science ®Google Scholar
• Aypar E, Alehan D, Karagöz T, Aykan H, Ertugrul İ. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiol Young. 2020;30:681–685. doi:10.1017/S1047951120000773
   PubMed Web of Science ®Google Scholar
• Cadenas-Menéndez S, Álvarez VP, Oterino MA, et al. Evolution of patients with pulmonary arterial hypertension starting macitentan after the discontinuation of other endothelin-receptor antagonists: results of a Retrospective Study. Am J Cardiovasc Drugs. 2019.
   Web of Science ®Google Scholar
• Safdar Z, Thakur A, Frost A. Tolerability of switch to macitentan from bosentan in pulmonary arterial hypertension. South Med J. 2017;110:223–228. doi:10.14423/SMJ.0000000000000607
   PubMed Web of Science ®Google Scholar
• Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the “Treatment satisfaction with medicines questionnaire” (SATMED-Q). Value in health: the. j Int Soc Pharmacoecon Outcomes Res. 2008;11:913–926.
   Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903. doi:10.1183/13993003.01032-2015
   PubMed Web of Science ®Google Scholar
• Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th world symposium on pulmonary hypertension: what’s old is new. F1000Research. 2019;8:8. doi:10.12688/f1000research.18811.1
   PubMedGoogle Scholar
• Frantz RP, Durst L, Burger CD, et al. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. J Cardiovasc Pharmacol Ther. 2014;19:550–557. doi:10.1177/1074248414528066
   PubMed Web of Science ®Google Scholar
• Lichtblau M, Harzheim D, Ehlken N, et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung. 2015;193:105–112. doi:10.1007/s00408-014-9657-7
   PubMed Web of Science ®Google Scholar
• Shapiro S, Traiger G, Hill W, Zhang L, Doran AK. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013;31:274–279. doi:10.1111/1755-5922.12038
   PubMed Web of Science ®Google Scholar
• Tay EL, Geok-Mui MK, Poh-Hoon MC, Yip J. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int J Cardiol. 2008;125:416–417. doi:10.1016/j.ijcard.2007.01.046
   PubMed Web of Science ®Google Scholar
• Shlobin OA, Brown AW, Weir N, Ahmad S, Lemma M, Nathan SD. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. Lung. 2012;190:573–578. doi:10.1007/s00408-012-9408-6
   PubMed Web of Science ®Google Scholar
• Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transpl. 2007;26:63–69. doi:10.1016/j.healun.2006.10.019
   PubMed Web of Science ®Google Scholar
• McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135:122–129. doi:10.1378/chest.08-1028
   PubMed Web of Science ®Google Scholar
• Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Vasc Health Risk Manag. 2011;7:119–124. doi:10.2147/VHRM.S15026
   PubMedGoogle Scholar
• Fox B, Langleben D, Hirsch AM, et al. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. Can J Cardiol. 2013;29:672–677.
   PubMed Web of Science ®Google Scholar
• Gong SG, Wang L, Pudasaini B, et al. Transition from ambrisentan to bosentan in pulmonary arterial hypertension: a single-center prospective study. Canadian Respir J. 2018;2018:9836820. doi:10.1155/2018/9836820
   PubMed Web of Science ®Google Scholar